| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Fz7-21S is a negative control peptide that does not target FZD7 receptors. It is designed to have a similar sequence or structure to the active antagonist Fz7-21 but with modifications that abolish its binding or activity. This allows researchers to distinguish specific FZD7-mediated effects from non-specific effects of the peptide in Wnt signaling studies.
|
|---|---|
| ln Vitro |
In vitro, Fz7-21S is used as a negative control in cell-based assays to confirm the specificity of Fz7-21's activity. Cells are treated with Fz7-21S alongside Fz7-21, and downstream Wnt signaling readouts (e.g., β-catenin accumulation, TCF/LEF reporter activity) are compared. Fz7-21S should not inhibit Wnt signaling, thereby confirming that any observed inhibition by Fz7-21 is specifically due to FZD7 antagonism.
|
| ln Vivo |
In vivo, Fz7-21S serves as a negative control in animal studies to validate the specificity of Fz7-21's effects. By comparing the effects of Fz7-21 and Fz7-21S in tumor models or other disease models, researchers can confirm that the observed therapeutic effects are specifically due to FZD7 antagonism rather than non-specific peptide effects. The use of a negative control is essential for establishing the mechanism of action of the active compound.
|
| Enzyme Assay |
Non-cellular binding assays for Fz7-21S involve testing its ability to bind to FZD7 receptors in comparison to Fz7-21. Binding affinity is measured using techniques such as surface plasmon resonance (SPR), radioligand binding, or fluorescence polarization. Fz7-21S should show minimal or no binding to FZD7, confirming its role as a negative control. These assays validate the specificity of the active antagonist.
|
| Cell Assay |
In vitro cellular experiments with Fz7-21S are performed alongside Fz7-21 to validate the specificity of the active compound's effects. Cells expressing FZD7 receptors are treated with Fz7-21 or Fz7-21S, and Wnt signaling activity is assessed using luciferase reporter assays or by measuring β-catenin levels. Fz7-21S should not affect Wnt signaling, confirming that any effects of Fz7-21 are specifically mediated through FZD7 antagonism.
|
| Animal Protocol |
In vivo animal studies using Fz7-21S are conducted alongside studies with Fz7-21 to validate the specificity of the active compound's effects in vivo. Animal models of disease (e.g., cancer xenografts) are treated with Fz7-21 or Fz7-21S, and tumor growth or other disease parameters are monitored. Fz7-21S should show no effect, confirming that the effects of Fz7-21 are specifically due to FZD7 targeting.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Fz7-21S include a molecular formula of C83H114N18O24S and a molecular weight of 1779.96. The CAS number is 2247635-24-9. The compound appears as a solid. It is typically shipped with blue ice. Storage conditions should follow the supplier's recommendations. The compound is for research use only and is not for human therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicity data for Fz7-21S are not typically characterized as it is a negative control peptide used in research assays rather than a therapeutic agent. Standard laboratory safety precautions should be followed when handling the compound. Researchers should consult the safety data sheet for specific handling and disposal guidelines. The compound is for research use only.
|
| References | |
| Additional Infomation |
Fz7-21S is a negative control for Fz7-21, a potent peptide antagonist of FZD7 receptors. FZD7 is a receptor involved in Wnt signaling. The compound is used to validate the specificity of Fz7-21's effects in experimental studies. All products are for research use only and not for human therapeutic applications.
|
| CAS # |
2247635-24-9
|
|---|---|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~56.18 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
